| DC7133 |
GGTI-DU40 |
GGTI-DU40 is highly selective inhibitor for GGTase-I both in vitro and in living cells. Studies indicate GGTI-DU40 blocks prenylation of a number of geranylgeranylated CaaX proteins. Treatment of MDA-MB-231 breast cancer cells with GGTI-DU40 inhibited thr |
|
| DC11246 |
Ghrelin agonist HM01
Featured
|
Ghrelin agonist HM01 is a novel potent, orally available ghrelin (GHS-R) agonist with Ki of 1.42 nM (human GHS-R1a), induces potent activation of intracellular calcium signaling with EC50 of 1.25 nM. |
|
| DC8873 |
GHRP-2 Acetate |
GHRP-2 is a synthetic hexapeptide Growth Hormone Releasing Peptide (GHRP), which acts on the hypothalamus and the pituitary gland to release growth hormone with a slight stimulator effect on Prolactin, ACTH and Cortisol levels. |
|
| DC10883 |
GI254023X
Featured
|
GI254023X is a potent MMP9 and ADAM10 inhibitor with IC50s of 2.5 and 5.3 nM, respectively. |
|
| DC23592 |
GI-530159 |
GI-530159 (ICA-069771) is a novel potent, selective, mechano-sensitive K2P channel (TERK) opener with EC50 of 1 uM for TERK1. |
|
| DC10490 |
GIBH-130
Featured
|
GIBH-130 is a novel inhibitor of neuroinflammation effective in Alzheimer’s disease models. |
|
| DC8946 |
Gimeracil |
Gimeracil(Gimestat) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood; inhibits homologous recombination. |
|
| DC7432 |
Givinostat (ITF2357)
Featured
|
Givinostat (ITF2357) is a potent HDAC inhibitor for maize HD2, HD1B and HD1A with IC50 of 10 nM, 7.5 nM and 16 nM. Phase 1/2. |
|
| DC10081 |
GJ103
Featured
|
GJ103 is an active analog of the read-through compound GJ072. |
|
| DC10080 |
GJ103 (sodium salt)
Featured
|
GJ103 sodium salt is an active analog of the read-through compound GJ072. |
|
| DC22099 |
GK563 |
GK563 (GK-563) is a potent, selective inhibitor of Ca2+-independent phospholipase A2 (GVIA iPLA2) with IC50 of 1 nM, >20,000-fold selectivity over GIVA cPLA2. |
|
| DC9855 |
GK921
Featured
|
GK921 is a transglutaminase 2 (TGase 2) inhibitor with average GI50 of 0.9 uM in cancer cell lines. |
|
| DC20087 |
GKI-1 |
GKI-1 is a Greatwall (GWL) kinase inhibitor with IC50s of 4.9 and 2.5 µM against hGWLFL and hGWL-KinDom, respectively. GKI-1 robustly inhibits ROCK1 with an IC50 of 11 µM, but only weakly affected PKA. |
|
| DC8118 |
GKT137831(Setanaxib)
Featured
|
GKT137831 is a novel and specific dual Nox1/Nox4 inhibitor with Ki of 140±40 nM and 110±30 nM; a potent inhibitor of fibrosis and hepatocyte apoptosis. |
|
| DC23332 |
GL-1196 |
GL-1196 is a PAK4 inhibitor that effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclinD1 pathway and CDK4/6 expression. |
|
| DC21049 |
Glabrescione B
Featured
|
Glabrescione B (GlaB) is a small molecule binding to Gli1 zinc finger and impairing Gli1 activity by interfering with Gli1/DNA interaction, inhibits Hh signaling by impairing Gli1 function; inhibits the growth of Hedgehog-dependent tumor cells in vitro and in vivo, inhibits Gli1-dependent growth of cerebellum-derived normal progenitors; inhibits the growth of Gli-dependent medulloblastoma and tumor-derived stem-like cells; inhibits the growth of Gli-dependent basal cell carcinoma in vitro and in vivo. |
|
| DC10130 |
Glabridin
Featured
|
Glabridin is a bio-available isoflavan isolated from licorice (Glycyrrhiza glabra L.) root extract |
|
| DC10818 |
ABT-493(Glecaprevir)
Featured
|
Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. |
|
| DC22566 |
Glesatinib hydrochloride |
Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase.. |
|
| DC25053 |
Glesatinib |
Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase.. |
|
| DC9158 |
Glimepiride |
Glimepiride(Amaryl) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg. |
|
| DC9146 |
Glipizide |
Glipizide is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes. |
|
| DC12257 |
Gln-AMS TFA |
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 µM. |
|
| DC12354 |
Gln-AMS |
Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes. |
|
| DC12223 |
GLP-1 receptor agonist-1 |
GLP-1 receptor agonist-1 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. |
|
| DC10319 |
GLP-17-3 |
GLP-1(7-36) is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells. |
|
| DC11296 |
GLP-26
Featured
|
GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM. |
|
| DC21051 |
GLPG 0974 |
GLPG 0974 is a potent, selective free fatty acid receptor 2 (FFA2, GPR43) antagonist with IC50 of 95 nM. |
|
| DC8375 |
GLPG0634 analogue
Featured
|
GLPG0634 (analog) is a pan JAK inhibitor with IC50s of 50-200 nM for JAK1/JAK2/JAK3; more information can be found in the reference patents. |
|
| DC11803 |
GLPG-1690(Ziritaxestat)
Featured
|
GLPG-1690 is a first-in-class, potent, competitive autotaxin inhibitor with Ki/IC50 of 15 nM/131 nM. |
|
